Even More Trouble for FedEx After Earnings
FedEx reported disappointing quarterly results and lowered its guidance after the markets closed on Tuesday, and shares dipped in the after-hours.
All Work
Chris Lange
What to Watch When Micron Reports Wednesday
Micron Technology is set to report its most recent quarterly results after the markets close on Wednesday, and expectations are very different than a year ago.
Why This Multiple Sclerosis Study’s Positive Results May Not Be Enough
Adamas Pharma shares dropped sharply on Tuesday after the firm reported results from its late-stage multiple sclerosis study.
Why Accelerated Approval Could Be Huge for This Ovarian Cancer Study
ImmunoGen shares jumped on Tuesday after the FDA advised that a new single-arm study in platinum-resistant ovarian cancer could support accelerated approval.
What’s Next for the Proteostasis Cystic Fibrosis Pipeline
Proteostasis shares were absolutely crushed on Tuesday after the firm announced midstage data from its cystic fibrosis study. What comes next?
What to Expect When FedEx Reports After the Close
FedEx is scheduled to release its fiscal second-quarter financial results after the markets close on Tuesday.
Will This Dementia Treatment Be a Big Hit After FDA Decision?
Prevail Therapeutics shares jumped early on Tuesday after the firm announced that the FDA has granted Orphan Drug designation for its dementia treatment.
BlackBerry, Conagra, FedEx, Micron, Nike and More Earnings Coming This Week
24/7 Wall St. has put together a preview of FedEx, Nike and a few of the other most prominent earnings reports expected in the week before Christmas.
Pot Stocks on the Move After New Ontario Licensing Deal
Pot stocks were a little higher on Friday after the Ontario government announced that it will abandon the current lottery system for cannabis retail.
Are Analysts Too Optimistic on Lululemon After Earnings?
While this might be a great time for Lululemon investors to lock in their gains and take profits, analysts mostly are calling for the stock to continue its massive run.
Sarepta Catches a Big Break With Duchenne Muscular Dystrophy Drug
Sarepta shares jumped on Friday after the firm announced that the FDA has approved Vyondys 53 (golodirsen) for the treatment of Duchenne muscular dystrophy (DMD) in certain patients.
Does Costco Deserve More Credit for Q1 Earnings?
Costco reported mixed fiscal first-quarter financial results after the markets closed on Thursday, and shares pulled back early Friday.
Are Oracle Earnings Enough for Investors?
Oracle released fiscal second-quarter financial results after markets closed Wednesday. The firm said that it had $0.90 in earnings per share (EPS) and $9.62 billion in revenue, compared with consensus estimates that called for…
Why Wedbush Is Cautious on Homebuilders in 2020
Wedbush has a cautious view of many homebuilders for 2020 after noting that there will be tougher comps in the second half of the year while it actually sees the near-term setup as enticing.
Why This Analyst Is Staying on the Sidelines on Cisco
Cisco has been one of the weakest components of the Dow so far in 2019, and according to one analyst this might not change anytime soon.
Will Costco Keep Up the Pace With Earnings After the Close?
Costco is set to report its fiscal first-quarter financial results after the markets close on Thursday. Analysts are looking for year-over-year growth.
Wedbush’s Top Picks After ASH Annual Meeting
The American Society of Hematology (ASH) hosted its 61st annual meeting and one of the biggest biotech events earlier this week in Orlando, Florida.
What to Watch When Broadcom Reports
Broadcom is scheduled to release its fiscal first-quarter financial results after the markets close on Thursday.
What to Expect When Oracle Reports After the Close
Oracle is set to report its fiscal second-quarter financial results after the markets close on Thursday. The analysts are looking for year-over-year earnings growth.
Why These Breast Cancer Study Results Look So Promising
Puma Biotechnology shares made a handy gain early on Thursday after the company presented updated results from its Phase 2 Summit clinical trial of neratinib at the 2019 San Antonio Breast Cancer Symposium.